JULIA PERKINS: Open Payments
NPI 1235752841 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,039 in 61 payments from 16 companies in 2025. Trend: 2023 $1,218 · 2024 $1,481 · 2025 $1,039
Food & beverage: $1,039
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 10 | $192 |
| Dexcom, Inc. | 13 | $157 |
| Lilly USA, LLC | 7 | $115 |
| Novo Nordisk Inc | 6 | $113 |
| Astellas Pharma US Inc | 5 | $109 |
| Corcept Therapeutics | 5 | $98 |
| PFIZER INC. | 4 | $61 |
| Lundbeck LLC | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
Products named: TRELEGY ELLIPTA, Dexcom G6 Transmitter, Ozempic, Veozah, Korlym, MOUNJARO, REXULTI, ZEPBOUND.
Industry payments across AL — which companies pay providers there.
